Safety and Efficacy of Nusinersen Focusing on Renal and Hematological Parameters in Spinal Muscular Atrophy. [PDF]
Bahadır Şenol H+6 more
europepmc +1 more source
Spinal muscular atrophy in Ghanaian children confirmed by molecular genetic testing: a case series. [PDF]
Hammond CK+3 more
europepmc +1 more source
Administration practices of and adherence to nusinersen in children with spinal muscular atrophy: a multicenter disease registry study in China. [PDF]
Peng J+20 more
europepmc +1 more source
Risdiplam in Adult Patients With 5q Spinal Muscular Atrophy: A Single-Center Longitudinal Study. [PDF]
Gavriilaki M+4 more
europepmc +1 more source
Reduced white matter integrity and disrupted brain network in children with type 2 and 3 spinal muscular atrophy. [PDF]
Nie H+11 more
europepmc +1 more source
Sequential treatment with nusinersen, Zolgensma® and risdiplam in a paediatric patient with spinal muscular atrophytype 1: a case report. [PDF]
Bitetti I, Manna MR, Stella R, Varone A.
europepmc +1 more source
A self-reported Brazilian registry of 5q-spinal muscular atrophy: data on natural history, genetic characteristics, and multidisciplinary care. [PDF]
Mendonça RH, Godoi JSA, Zanoteli E.
europepmc +1 more source
Clinical and Genetic Profiles of 5q- and Non-5q-Spinal Muscular Atrophy Diseases in Pediatric Patients. [PDF]
Nishio H+7 more
europepmc +1 more source
Successful pregnancy of an SMA type 3 sitter on Nusinersen therapy - a case report. [PDF]
Hiebeler M, Thiele S, Walter MC.
europepmc +1 more source
Diagnostic Journey of Korean Patients with Spinal Muscular Atrophy. [PDF]
Kim SH+6 more
europepmc +1 more source